SCHEMBL4031734

SCHEMBL4031734

CN(CCO)S(=O)(=O)c1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 1/20 0.54
HTT P42858 1/20 0.47
PGR P06401 1/20 0.46
HCRTR2 O43614 1/20 0.45
KDM4E B2RXH2 3/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD11B1 P28845 4/20 0.44
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033271 0.87 MCOLN3 (0.55) GSTO1KDM4EHSD11B1ALDH1A1L3MBTL1
SCHEMBL12077622 0.85 PGR (0.47) GSTO1HTTPGRHCRTR2KDM4E
SCHEMBL7200353 0.81 ALDH1A1 (0.53) GSTO1HTTHCRTR2KDM4EHTR2A
SCHEMBL4033897 0.81 GSTO1 (0.46) GSTO1KDM4EHSD11B1ALDH1A1MCOLN3
SCHEMBL12077718 0.81 PGR (0.49) HTTPGRHCRTR2KDM4EHTR2A
SCHEMBL5117215 0.79 HTT (0.56) GSTO1HTTPGRHCRTR2KDM4E
SCHEMBL12169372 0.78 TSHR (0.47) GSTO1HTTKDM4EALDH1A1KMT2A
SCHEMBL5114284 0.77 HTT (0.48) GSTO1HTTPGRKDM4ECYP1A2
SCHEMBL3994492 0.76 RAB9A (0.47) GSTO1KDM4EHSD11B1ALDH1A1HSD17B10
SCHEMBL4029806 0.76 ALDH1A1 (0.64) GSTO1HTTKDM4EHSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 GSTO1 392/4885HTT 2903/4885PGR 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.